Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NeOnc Technologies Holdings, Inc. ( (NTHI) ) has shared an update.
On December 1, 2025, NeOnc Technologies Holdings, Inc. announced a Securities Purchase Agreement with investor Saad Naja for the sale of 111,732 shares of common stock at $8.95 per share, raising approximately $1 million to be used for working capital. Additionally, NeOnc revealed preclinical findings from a collaboration with the University of Southern California, showing that ultrasound enhances the effectiveness of NEO100 in treating brain tumors, potentially expanding its clinical and commercial opportunities.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company that focuses on developing and commercializing therapeutics for central nervous system cancers. The company is known for its NEO drug development platform, which includes novel drug candidates and delivery methods with patent protections extending to 2038. NeOnc’s products, such as NEO100 and NEO212, are in Phase II clinical trials and have shown promise in treating malignant gliomas.
Average Trading Volume: 83,165
Technical Sentiment Signal: Strong Buy
Current Market Cap: $182.1M
For detailed information about NTHI stock, go to TipRanks’ Stock Analysis page.